KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Cash & Equivalents (2016 - 2025)

Merck (MRK) has disclosed Cash & Equivalents for 17 consecutive years, with $14.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 9.99% to $14.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $14.6 billion, a 9.99% increase, with the full-year FY2025 number at $14.6 billion, up 9.99% from a year prior.
  • Cash & Equivalents was $14.6 billion for Q4 2025 at Merck, down from $18.2 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $18.2 billion in Q3 2025 to a low of $5.6 billion in Q1 2024.
  • A 5-year average of $10.0 billion and a median of $9.2 billion in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 46.11% in 2023, then soared 99.72% in 2024.
  • Merck's Cash & Equivalents stood at $8.1 billion in 2021, then surged by 56.79% to $12.7 billion in 2022, then plummeted by 46.11% to $6.8 billion in 2023, then soared by 93.57% to $13.2 billion in 2024, then increased by 9.99% to $14.6 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Cash & Equivalents are $14.6 billion (Q4 2025), $18.2 billion (Q3 2025), and $8.0 billion (Q2 2025).